lutetium has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Hee, C; Ho, D; Iyer, KS; Karton, A; Kretzmann, JA; Nealon, G; Norret, M | 1 |
| Blakkisrud, J; Dahle, J; Kolstad, A; Løndalen, A; Martinsen, AC; Stokke, C | 1 |
| Dahle, J; Eiríksdóttir, B; Larsen, RH; Malenge, MM; O'Shea, A; Repetto-Llamazares, AHV; Stokke, T | 1 |
| Alcarde, LF; Araújo, EB; Massicano, AV; Pujatti, PB; Spencer, PJ; Suzuki, MF | 1 |
| Dahle, J; Didierlaurent, D; Fleten, KG; Larsen, RH; Patzke, S; Pichard, A; Pouget, JP; Repetto-Llamazares, AH | 1 |
| Blakkisrud, J; Dahle, J; Holte, H; Kolstad, A; Løndalen, A; Stokke, C; Turner, S | 1 |
| Bardiès, M; Courteau, A; Dahle, J; Heyerdahl, H; Ladjohounlou, R; Marcatili, S; Navarro-Teulon, I; Pichard, A; Pouget, JP; Repetto-Llamazares, A | 1 |
| Chen, J; Fani, M; Forrer, F; Lohri, A; Maecke, HR; Moldenhauer, G; Müller-Brand, J; Powell, P | 1 |
| Baechler, S; Boubaker, A; Dieudonné, A; Gardin, I; Hobbs, RF; Le Guludec, D; Lebtahi, R; Maurel, F; Sgouros, G; Wahl, RL | 1 |
| Dahle, J; Larsen, RH; Lassmann, M; Mollatt, C; Repetto-Llamazares, AH | 1 |
| Bruland, OS; Dahle, J; Kolstad, A; Larsen, RH; Melhus, KB; Mollatt, CS; Repetto-Llamazares, AH | 1 |
1 trial(s) available for lutetium and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Cell Line; Chelating Agents; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Lutetium; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Mice; Pilot Projects; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Rituximab; Yttrium Radioisotopes | 2009 |
10 other study(ies) available for lutetium and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Macromolecular approach for targeted radioimmunotherapy in non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents, Immunological; Cell Survival; Click Chemistry; Epoxy Compounds; Humans; Immunoconjugates; Lutetium; Lymphoma, Non-Hodgkin; Methacrylates; Polymers; Radioimmunotherapy; Rituximab | 2019 |
Myelosuppression in patients treated with
Topics: Antibodies, Monoclonal; Bone Marrow; Humans; Immunoconjugates; Lutetium; Lymphoma, Non-Hodgkin; Radiometry | 2021 |
Combination of
Topics: Animals; Antibodies, Monoclonal; Antigens, CD20; Biomarkers; Cell Line, Tumor; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Gene Expression; Humans; Immunoconjugates; Immunophenotyping; Lutetium; Lymphoma, Non-Hodgkin; Mice; Mice, Nude; Mice, SCID; Radioisotopes; Rituximab; Xenograft Model Antitumor Assays | 2018 |
Development and biological studies of ¹⁷⁷Lu-DOTA-rituximab for the treatment of Non-Hodgkin's lymphoma.
Topics: Animals; Drug Stability; Humans; Lutetium; Lymphoma, Non-Hodgkin; Mice; Mice, SCID; Radiopharmaceuticals; Rituximab; Succinimides; Tissue Distribution; Xenograft Model Antitumor Assays | 2016 |
Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.
Topics: Animals; Antibodies; Antigen-Antibody Reactions; Antigens, Neoplasm; Beta Particles; Cell Line, Tumor; Disease Models, Animal; Humans; Immunoconjugates; Iodine Radioisotopes; Lutetium; Lymphoma, Non-Hodgkin; Mice; Mice, Nude; Radioisotopes; Radiopharmaceuticals; Rituximab; Tetraspanins; Tissue Distribution; Transplantation, Heterologous | 2015 |
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate.
Topics: Absorption, Radiation; Adult; Antibodies, Monoclonal; Antigens, Neoplasm; Bone Marrow; Female; Humans; Lutetium; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Reproducibility of Results; Sensitivity and Specificity; Tetraspanins; Treatment Outcome | 2017 |
Realistic multi-cellular dosimetry for
Topics: Antineoplastic Agents; Humans; Lutetium; Lymphoma, Non-Hodgkin; Models, Biological; Monte Carlo Method; Radiometry; Radiopharmaceuticals; Rituximab; Software; Tissue Distribution; Tumor Cells, Cultured | 2016 |
Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods.
Topics: Antibodies, Monoclonal; Carcinoma, Hepatocellular; Humans; Imaging, Three-Dimensional; Iodine Radioisotopes; Liver Neoplasms; Lutetium; Lymphoma, Non-Hodgkin; Microspheres; Models, Statistical; Monte Carlo Method; Neuroendocrine Tumors; Radioisotopes; Radiometry; Radionuclide Imaging; Radiotherapy Dosage; Yttrium Radioisotopes | 2013 |
Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma.
Topics: Animals; Case-Control Studies; Female; Humans; Lutetium; Lymphoma, Non-Hodgkin; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Radiation Dosage; Radioisotopes; Tissue Distribution | 2013 |
Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Humans; Immunoconjugates; Immunotherapy; Lutetium; Lymphoma, Non-Hodgkin; Mice; Mice, SCID; Radioisotopes; Rituximab; Tetraspanins; Tissue Distribution | 2013 |